BSE filing, NSE: LALPATHLAB. Summary written from the filing by ALFA Finder's alert engine.
Dr. Lal Pathlabs Ltd: key numbers
- Share price
- ₹1,922.30
- Market cap
- ₹32,266 Cr
- Revenue (annual)
- ₹2,763 Cr
- Net profit (annual)
- ₹504.8 Cr
- P/E (TTM)
- 59.5×Sector 52.0×
- Promoter holding
- 52.93%-0.26% QoQ
- FII holding
- 18.73%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Lal Pathlabs Ltd
All →Dr. Lal Pathlabs Board Meeting Date
Dr. Lal PathLabs updated its 4 November 2026 board meeting notice to add a possible second interim dividend. The meeting will also approve unaudited quarterly results.
Dr. Lal Pathlabs Acquisition Worth ₹30.3 Cr
Dr. Lal PathLabs subscribed to WOS PUPL equity to fund PUPL's buyout of remaining 30% in CentraPath Labs for ₹30.3 Crore. CentraPath becomes a wholly owned subsidiary.
- Value
- ₹30.30 Cr
Dr. Lal Pathlabs Other Announcement
Dr. Lal PathLabs submitted the quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, received from its RTA.
Dr. Lal Pathlabs Legal & Regulatory
Dr. Lal PathLabs disclosed an ITAT tax appeal against a favorable order for Rs.32.66 Crore ESOP expense relief (AY 2022-23). The company expects no material financial impact.
- Value
- ₹32.66 Cr
Dr. Lal Pathlabs Other Announcement
Dr. Lal PathLabs reported PIT disclosures for trades by designated persons and its Employee Welfare Trust, totaling approximately ₹0.83 Crore. These involved ESOP allotments and market sales.
- Value
- ₹0.09 Cr
Dr. Lal Pathlabs Acquisition Worth ₹38 Cr
Dr. Lal Path Labs' subsidiary completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana, for Rs.38.00 Crore. The target is now a subsidiary.
- Value
- ₹38.00 Cr
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.